Topline clinical data from ALS Phase 2b PARADIGM trial of PrimeC combination therapy is expected Q4 2023; Company is fully funded into Q2 2024
CAMBRIDGE, Mass., Oct. 2, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq:NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it has terminated its previously established "at-the-market" ("ATM") equity offering program. The termination will take effect at the close of business on October 4th, 2023, following the 3-day termination process of the ATM offering
Read more at prnewswire.com